Nathaniel Gaeckle,1 Edward Corazalla,2 Judy S Kelloway,3 Joshua N Liberman,4 Jonathan David Darer,4 Kristin Kahle-Wrobleski,5 Rosirene Paczkowski,5 Purva Parab,4 Charles Ruetsch4 1Division of Pulmonary, Allergy, Critical Care and Sleep, University of Minnesota, Minneapolis, MN, USA; 2Pulmonary Function Test Laboratory, M Health Fairview, University of Minnesota, Minneapolis, MN, USA; 3US Medical Affairs, GSK, Research Triangle Park, Durham, NC, USA; 4Health Analytics LLC, Clarksville, MD, USA; 5US Value Evidence and Outcomes, GSK, Philadelphia, PA, USACorrespondence: Nathaniel Gaeckle, Department of Medicine, University of Minnesota, 420 Delaware Street SE, MMC 276, Minneapolis, Minnesota, 55455, USA, Tel +001-612-624-0999, Fax +001-612-625-2174, Email [email protected]: The Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) measures COPD’s impact on well-being and daily activities and is a recommended assessment by the Global Initiative for Obstructive Lung Disease (GOLD). Our research objective was to describe a real-world CAT implementation, including the association of CAT scores with subsequent treatment and clinical outcomes.Patients and Methods: A retrospective, observational, comparative cohort study was conducted among adults with COPD who received care from M Health Fairview, a US healthcare delivery system. Eligible patients had an initial electronic health record (EHR) enabled CAT administration (index) between 8/2017 and 12/2021. Patients were grouped by score (< 10 [low impact]; 11– 20 [moderate]; and 21– 40 [high]). Demographics, comorbidities, provider specialty, and exacerbation history were derived from EHR data in the 12 months preceding index.Results: Of 11,194 eligible individuals, 821 (7.3%) were administered CAT (cases). Compared to individuals with no documented CAT scores (comparators), cases were older (66.7 vs 63.9 years; p < 0.05) and had higher rates of comorbidities (93.9% vs 79.2%, p < 0.05) and exacerbations (0.31 vs 0.14 PPPY). A total of 61.5% of pulmonologists and 11.5% of primary care providers (PCPs) administered the CAT at least once. Repeated use was more common among pulmonologists (55.7%) than PCPs (7.0%). Medication intensification was most common (28.1%) among individuals with high CAT scores, followed by moderate (21.6%), and low (10.0%). Post-index exacerbations were experienced by 24.2%, 17.4%, and 7.7% of patients with high, moderate, and low CAT scores.Conclusion: In a real-world practice setting, few patients with COPD received a CAT, although pulmonologists demonstrated repeated use. Higher CAT scores were associated with COPD medication regimen intensification and exacerbations. Further investigation on how to incorporate the CAT into routine care and optimize its impact on medical decision making and evaluation is warranted.Keywords: Pulmonary Disease, Chronic Obstructive, MeSH, Patient Reported Outcome Measures, MeSH, Clinical Relevance, MeSH, COPD Assessment Tes
